Tag Archives: Celldex Therapeutics

Business, Finance, Occupation & Industry

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Resu

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013

BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (NAS: SGEN) announced today that it will report its first quarter 2013 financial results on Tuesday, May 7, 2013, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Tuesday, May 7, 2013
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

REPLAY access

  • Telephone replay will be available beginning at approximately 3:30 p.m. PT on Tuesday, May 7, 2013 through 5:00 p.m. PT on Thursday, May 9, 2013 by calling 800-406-7325 (domestic) or 303-590-3030 (international); conference ID 4614604
  • Webcast replay will be available on the Seattle Genetics website at http://www.seattlegenetics.com/ in the Investors and News section

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The company’s lead program, ADCETRIS® (brentuximab vedotin), received accelerated approval from the U.S. Food and Drug Administration in August 2011 and approval with conditions from Health Canada in February 2013 for two indications. In addition, under a collaboration with Millennium: The Takeda Oncology Company, ADCETRIS received conditional marketing authorization from the European Commission in October 2012. Seattle Genetics also has four other clinical-stage ADC programs: SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Agensys (an affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at www.seattlegenetics.com.

From: http://www.dailyfinance.com/2013/04/18/seattle-genetics-to-host-conference-call-and-webca/

Business, Finance, Occupation & Industry

3 Humongous Health-Care Stocks This Week

Leave a comment

By Keith Speights, The Motley Fool

Filed under:

The Dow set an all-time high, but it still was up only 2% for the week. If you want returns to really get excited about, look no further than the health-care sector. Here are three stocks that churned out humongous gains this week.

Mad money?
Shares in Astex Pharmaceuticals soared this week by nearly 37%. This was a huge jump considering there was no major news. So what happened?

The one significant event this week related to Astex was that TheStreet.com upgraded the stock from “hold” to “buy.” However, that upgrade occurred on Monday, while shares didn’t really take off until Wednesday. Once the buying frenzy started, it didn’t stop. The stock continued to climb strongly through the end of the week.

Trading volume for each of the last three days of the week was around four times higher than normal. It could be lots of smaller investors with mad money to spend. My guess, though, is that some entity with deep pockets is buying Astex like crazy. I won’t be surprised if we find out later that a hedge fund or other large investor scooped up big chunks of the stock.

Less loss equals big gain
There wasn’t much mystery behind the major moves for stem cell company Osiris Therapeutics . Shares surged nearly 35% for the week after the company posted better-than-expected earnings results.

Osiris reported a net loss of $0.08 per share, compared with a $0.15-per-share gain in the same quarter of the prior year. However, analysts were expecting the loss to be much worse at $0.15 per share. Osiris also reported $3.1 million in revenue, down from $11 million in the same quarter for 2011. The big year-over-year difference stemmed from Sanofi‘s cancellation of an agreement in early 2012.

Look for revenue to pick up for Osiris now that the company has built a direct sales force for Grafix, its wound healing implant for diabetic foot ulcers and other serious wounds. Its sales team currently focuses on 10 major metropolitan areas. The company expects to double this direct sales force over the coming year. 

Roller-coaster ride
Up, down, then back up gain. Celldex Therapeutics shareholders had to hold on tight, but their shares ended up on a high note, closing 20% higher for the week.

The stock eased higher earlier in the week as investors awaited the fourth-quarter earnings announcement before the market opened on Thursday. However, the results were disappointing, as Celldex missed analysts’ earnings estimates. Shares fell 17% — but only temporarily.By the end of the day, most of that loss was wiped out.

Friday was a different story. Celldex surged after investment firm Cantor raised its price target for the stock from $13 to $16 per share. Cantor’s rationale was that it now expects Celldex to see revenue from CDX-011 and rindopepimut in 2016 rather than 2017.

Pick of the week
Gains of 20% to 37% in one week are great. Unfortunately, they can also be fleeting. Which of the …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Why Celldex Shares Dropped

Leave a comment

By Jeremy Bowman, The Motley Fool

Filed under:

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.

What: Shares of Celldex Therapeutics were getting rejected by investors today, falling as much as 17% after reporting earnings this morning.

So what: Celldex reported a $0.27 per share loss on revenue of $3.6 million. Earnings missed estimates, while sales beat them, but that is mostly irrelevant since Celldex is a development-stage biopharmaceutical company. Overall, the report looks strong with the company showing positive data from a phase 2b study of CDX-011 in metastatic breast cancer, as well as encouraging survival data from phase 2 studies of rindopepimut. The company’s cash position also improved over 2012, adding $30 million through additional financing, which management said will “support operations and clinical development through 2015.”

Now what: Today’s drop could simply be a secular pullback as Celldex shares have gained 300% since October 2011 — and nearly 50% this year alone. With no major immediate breakthroughs on the way, shares seemed due to cool off a bit. Investors may also be reacting to recent share dilution, which was needed to fund R&D. In the first two months of the year, Celldex sold 16 million more shares, diluting investors by 25%. After a volatile opening today, shares have climbed and the stock was down just 5% by midday.

While you can certainly make huge gains in biotech companies like Celldex, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool’s free report “3 Stocks That Will Help You Retire Rich” names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Why Celldex Shares Dropped originally appeared on Fool.com.

Fool contributor Jeremy Bowman has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

5 of Last Week's Biggest Winners

Leave a comment

By Rick Aristotle Munarriz, The Motley Fool

Filed under:

What’s better than momentum? Mo’ momentum. Let’s take a closer look at five of this past week’s biggest scorchers.

Company

March 1

Weekly Gain

MediciNova

$2.98

47%

MGIC Investment

$3.79

39%

MAKO Surgical

$12.75

13%

Ebix

$15.33

11%

Celldex Therapeutics

$10.26

10%

Source: Barron’s.

MediciNova was an obscure and thinly traded biotech until it received fast-track designation from the FDA for its potentially promising treatment of methamphetamine dependence on Monday afternoon. Fast-track status grants an expedited review of drugs that aim to fill an unmet medical niche or treat serious diseases. More than 6 million shares of MediciNova traded hands last week, and it’s safe to say that MediciNova will no longer be an obscure and thinly traded biotech.

MGIC soared despite posting its 10th consecutive quarterly loss on Thursday. The shares rallied on the market’s confidence that home prices in general will continue to firm, making MGIC’s dicey portfolio less risky.

MAKO Surgical also bounced back after posting uninspiring financial results. They key here is that the company behind the RIO surgical robotics system for orthopedic procedures had already braced investors for the soft showing back in January. The market was won over by its cautious outlook for the year ahead, calling for the sale of 45 to 48 new RIO systems and roughly 13,500 to 14,500 procedures for all of 2013.

Ebix bounced back after getting pounded a week earlier on a bearish report. The insurance industry software specialist rose after hosting a conference call to refute the negative claims in the report. Ebix was apparently convincing enough to gain back a good chunk of the prior week’s hit.

Celldex Therapeutics has now come through with three straight weeks featuring gains of 8% or better. Momentum continues to build after revealing positive test results for its treatment for hematopoietic stem cell transplantation last month.

Keep the good vibes coming
To learn more about a few ETFs that have great promise for delivering profits to shareholders in a recovering global economy, check out The Motley Fool’s special free report “3 ETFs Set to Soar During the Recovery.” Just click here to access it now.

The article 5 of Last Week’s Biggest Winners originally appeared on Fool.com.

Longtime Fool contributor Rick Aristotle Munarriz owns shares of Ebix. The Motley Fool recommends Ebix and MAKO Surgical and owns shares of Ebix. Try any of our Foolish newsletter services free for 30 days. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
…read more
Source: FULL ARTICLE at DailyFinance